NCT00133471View on ClinicalTrials.gov

Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza A/H9N2 vaccine

A single lot of monovalent inactivated SA influenza A/H9N2 vaccine. All injections will be administered in a 0.5-mL volume into the deltoid muscle. Dosage levels are: 3.75-, 7.5-, 15-, and 30-mcg of HA of the vaccine strain with and without MF59 adjuvant.

DRUG

MF59 adjuvant

MF59 adjuvant is an oil-in-water emulsion.

Trial Locations (1)

77030

Baylor College of Medicine, Houston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00133471 - Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults | Biotech Hunter | Biotech Hunter